Microbot Medical shares surge 11.35% premarket after H.C. Wainwright reaffirms Buy rating and $12 price target following first hospital adoption of LIBERTY system.

Microbot Medical (MBOT) surged 11.35% in premarket trading following the announcement that Emory University Hospital became the first institution to adopt its LIBERTY Endovascular Robotic System for patient care. This milestone, coupled with H.C. Wainwright’s reaffirmed Buy rating and $12.00 price target, underscored growing commercial momentum for the system, which was recently cleared for U.S. use. The partnership with Emory, a leader in endovascular and oncology services, highlights the system’s potential to enhance precision in procedures like liver tumor embolization, while Wainwright’s positive outlook anticipates broader hospital adoption. The news aligns with the company’s Limited Market Release strategy, targeting high-demand regions, and reinforces confidence in the LIBERTY system’s market viability ahead of its full 2026 launch.